Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,861 matching trials from the live ClinicalTrials.gov search.
Filters: Chapel Hill, North Carolina Clear all
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

NCT01998633
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Months to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 31, 2026, 4:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MGL-3196, Placebo, Liver Biopsy
Drug · Procedure
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
90
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 31, 2026, 4:37 AM EDT
Completed No phase listed Observational

Biomarkers in Blood Samples From Older Breast Cancer Survivors

NCT01138345
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, medical chart review, questionnaire administration
Genetic · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

NCT00371345
View directory record Official record
Conditions
Breast Cancer, Metastasis
Interventions
Dasatinib, Dasatinib 100 mg
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
San Francisco, California • Jacksonville, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 31, 2026, 4:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722
View directory record Official record
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Interventions
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Drug
Lead sponsor
enGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modulation of Cognitive Control Signals in Prefrontal Cortex by Rhythmic Transcranial Magnetic Stimulation

NCT03828734
View directory record Official record
Conditions
Executive Function
Interventions
Theta TMS, Alpha TMS, Arrhythmic TMS
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality

NCT03720847
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Estradiol Transdermal Patch 0.1 mg/24 hrs, Oral Micronized Progesterone, Inactive Clear Patch, Placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Impact of Warnings on Sugar-Sweetened Beverages

NCT04223687
View directory record Official record
Conditions
Dietary Habits
Interventions
Sugar-Sweetened Beverage Warning Label, Neutral label
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 31, 2026, 4:37 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133
View directory record Official record
Conditions
Breast Neoplasms
Interventions
LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, Pertuzumab, Loperamide, Endocrine therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
13
States / cities
Rogers, Arkansas • La Jolla, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Auditory Cues on Gait Mechanics in Parkinson's Disease

NCT03253965
View directory record Official record
Conditions
Parkinson Disease
Interventions
Metronome Normal, Metronome Slow, Metronome Fast, Music Normal, Music Slow, Music Fast, No Auditory cueing
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

Adaptive Goals and Interventions for Lifestyle Enhancement

NCT04922216
View directory record Official record
Conditions
Obesity
Interventions
Core, Standard Diet Monitoring, Simplified Diet Monitoring, Adaptive Activity Goals (Daily), Adaptive Activity Goals (Weekly), Message Decision Points (Fixed), Message Decision Points (Adaptive), Message Decision Rules (Standard), Message Decision Rules (Adaptive), Message Choice (No), Message Choice (Yes)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 39 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 31, 2026, 4:37 AM EDT
Not listed Phase 2 Interventional

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers

NCT02973893
View directory record Official record
Conditions
Ulcer, Leg Ulcer, Varicose Ulcer, Pathologic Processes, Skin Ulcer, Skin Diseases, Vascular Diseases, Cardiovascular Diseases
Interventions
Placebo, VF001-DP LD, VF001-DP HD
Biological
Lead sponsor
Factor Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Carlsbad, California • Fresno, California • Laguna Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 31, 2026, 4:37 AM EDT
Terminated Phase 3 Interventional Results available

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206
View directory record Official record
Conditions
Primary Systemic (AL) Amyloidosis
Interventions
NEOD001, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
32
States / cities
Scottsdale, Arizona • Duarte, California • Stanford, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT02289833
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Trastuzumab Emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Jacksonville, Florida • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

NCT00071812
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
63
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Causal Role of Frontostriatal Circuitry in Goal-directed Behavior

NCT05593965
View directory record Official record
Conditions
Executive Function
Interventions
Delta-beta TMS, Theta-gamma TMS, Arrhythmic TMS
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Not applicable Interventional Results available

Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)

NCT00858130
View directory record Official record
Conditions
Post Thrombotic Syndrome, Deep Vein Thrombosis, Venous Stasis Syndrome, Venous Insufficiency, Postphlebitic Syndrome
Interventions
VeinOPlus
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 31, 2026, 4:37 AM EDT
Completed No phase listed Observational

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

NCT01206309
View directory record Official record
Conditions
Graft vs Host Disease, Cutaneous Sclerosis, Bronchiolitis Obliterans
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 31, 2026, 4:37 AM EDT
Not listed Phase 3 Interventional

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

NCT01886820
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
[18F]NAV4694
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
15
States / cities
Sun City, Arizona • La Jolla, California • Fort Myers, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 31, 2026, 4:37 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix

NCT00439374
View directory record Official record
Conditions
Preterm Delivery, Cervical Length
Interventions
17 alpha-hydroxyprogesterone caproate, Placebo Oil
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
657 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 31, 2026, 4:37 AM EDT
Completed No phase listed Observational

Evaluating Progression of and Diagnostic Tools for Primary Ciliary Dyskinesia in Children and Adolescents

NCT00450918
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
4
States / cities
Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 31, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Silymarin for Chronic Liver Diseases

NCT00389376
View directory record Official record
Conditions
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Silymarin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Oct 31, 2026, 4:37 AM EDT
Completed No phase listed Observational

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
2 Years and older
Enrollment
7,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
65
States / cities
Phoenix, Arizona • Palo Alto, California • Pasadena, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 31, 2026, 4:37 AM EDT